Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Bacon v. Stiefel Laboratories, Inc. et al
Case Number:
1:11-cv-20489
Court:
Nature of Suit:
Judge:
Firms
- Greenberg Traurig
- Greenspoon Marder
- Lubell Rosen
- Podhurst Orseck
- Serafini Law Office
- Winston & Strawn
Companies
Sectors & Industries:
-
December 23, 2014
Plaintiff Asks Fla. Judge To Deny Stiefel's Recusal Request
A Florida federal judge should deny Stiefel Laboratories Inc.'s new request that he withdraw from overseeing a suit involved the pharmaceutical giant's employee stock plan, a plaintiff said Monday, calling defense concerns "nothing but speculation and a misunderstanding that this court has already corrected once before."
-
December 08, 2014
Stiefel Labs Pushes For Judge's Recusal In ERISA Suit
Stiefel Laboratories Inc. on Monday asked a Florida federal judge to recuse himself from a lawsuit accusing the pharmaceutical giant of tricking employees into selling shares of company stock before a merger that closed at a much higher valuation, saying the judge had done so in a related case.
-
June 11, 2013
Ex-Stiefel Employee Says Co. Bilked Him Of Full Stock Price
A former Stiefel Laboratories Inc. employee on Tuesday asked a Florida federal court to grant him at least partial summary judgment in his suit accusing the company's directors of tricking employees into selling Stiefel shares back to the company at artificially low prices just before it was bought by GlaxoSmithKline PLC.